EP1660115B1 - Pharmaceutical combination of g-csf and plgf useful for blood stem cell - Google Patents
Pharmaceutical combination of g-csf and plgf useful for blood stem cell Download PDFInfo
- Publication number
- EP1660115B1 EP1660115B1 EP04763431A EP04763431A EP1660115B1 EP 1660115 B1 EP1660115 B1 EP 1660115B1 EP 04763431 A EP04763431 A EP 04763431A EP 04763431 A EP04763431 A EP 04763431A EP 1660115 B1 EP1660115 B1 EP 1660115B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- csf
- rhg
- day
- mobilization
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 27
- 210000004369 blood Anatomy 0.000 title abstract description 46
- 239000008280 blood Substances 0.000 title abstract description 46
- 101150062285 PGF gene Proteins 0.000 title 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract description 14
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 3
- 239000013543 active substance Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 238000011127 radiochemotherapy Methods 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 230000003039 myelosuppressive effect Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 description 22
- 238000011282 treatment Methods 0.000 description 18
- 210000005087 mononuclear cell Anatomy 0.000 description 17
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 15
- 241000282560 Macaca mulatta Species 0.000 description 15
- 102100035194 Placenta growth factor Human genes 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 230000003021 clonogenic effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 11
- 210000002960 bfu-e Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 210000003013 erythroid precursor cell Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 230000001483 mobilizing effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010051396 Delayed engraftment Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- This invention regards a combination of biologically active molecules for use in the mobilization of blood stem cells in a patient or subject in need thereof. More specifically, the invention provides a combination of G-CSF and P1GF particularly effective in stimulating the mobilization of peripheral blood progenitor cells (PBPCs) thereby increasing feasibility and efficacy of organ or cell transplantation and of chemo-radiotherapy protocols in tumor patients.
- PBPCs peripheral blood progenitor cells
- Allogeneic PBPCs represent the preferred stem cell source for HLA-matched SCT and the unique source for HLA-mismatched allografts 6,7,8,9,10,11 which is a potentially curative therapy for patients with high-risk leukemias lacking an HLA-matched related or unrelated donor, i.e., approximately 40% of the global population of patients who may benefit of allogeneic transplantation.
- Protocols used to mobilize autologous PBPCs in cancer patients include the use of myeloid growth factors alone or during recovery from cytotoxic chemotherapy, with the latter approach allowing optimal PBPC mobilization 12,13,14 .
- Mobilization of allogeneic PBPCs from healthy donors is usually achieved by short courses of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in doses ranging from 10 to 20 ⁇ g/kg/day 15,16,17,18 .
- rhG-CSF human granulocyte colony-stimulating factor
- Increased PBPC mobilization might be achieved by using molecules capable of interfering with the mechanism(s) regulating hematopoietic stem cell trafficking, i.e., transmigration through the luminal endothelium to extravascular bone marrow spaces in homing and the reverse in mobilization 30,31,32,33 .
- cytokines such as recombinant human (rh) granulocyte-macrophage colony-stimulating factor (rhGM-CSF) plus rhG-CSF 34 , interleukin-3 (rhIL-3) plus rhG-CSF or rhGM-CSF 35 , and PIXY-321 36 .
- enhancement of PBPC mobilization might be achieved by incorporating in the standard mobilization regimen early-acting cytokines, such as stem cell factor (rhSCF) 37,38 of flt-3 39 ligand, capable of expanding marrow progenitors, thus increasing the number of cells susceptible to subsequent mobilization by rhG-CSF.
- cytokines such as stem cell factor (rhSCF) 37,38 of flt-3 39 ligand
- Placental growth factor is a member of the vascular endothelial growth factor (VEGF) family and functions as an angiogenic amplifier by signaling through VEGF receptor-1 (VEGFR1).
- VEGF vascular endothelial growth factor
- VEGFR1 VEGF receptor-1
- adenoviral vector expressing human (h) P1GF has been shown to exert complex hematopoietic effects, including enhancement of bone marrow recovery following myelosuppression, and mobilization of hematopoietic progenitors.
- the administration of growth factors following injection of recombinant adenoviral vectors presents several major differences from the direct injection of a purified factor, and might not be predictive of its effects when administered according to the modalities used in the clinical setting.
- mice were injected intraperitoneally (IP) for 5 days with either control vehicle (PBS/MSA), rhG-CSF alone (10 ⁇ g/d), or a combination of rhG-CSF (10 ⁇ g/d) and recombinant murine (rm)P1GF (2.5-5 ⁇ g/d).
- IP intraperitoneally
- WBC white blood cell
- CFC colony-forming cells
- LTC-IC long-term culture-initiating cells
- rmP1GF The effects of rmP1GF are illustrated in Tables 1-4 below. It is evident that rmP1GF injected alone has no effect on the mobilization of WBC, CFC, and LTC-IC. A 5-day injection of rmP1GF (5 ⁇ g/d) combined with rhG-CSF significantly increases mobilization of CFC and LTC-IC, as compared to rhG-CSF alone.
- P1GF/G-CSF combinations were tested in a non-human primate model (Rhesus Monkeys). The results obtained in mice were further confirmed in this animal model.
- P1GF/G-CSF combination improved the mobilization of WBCs, CFCs, HPP-CFCs and LTC-ICs, in terms of kinetics, frequency and absolute numbers.
- Object of the invention is therefore a combined preparation of G-CSF and P1GF useful for stimulating blood stem cell mobilization in a patient or subject in need thereof.
- patient and “subject” preferably refer to human individuals, but they may also refer to animals, especially mammals.
- states, conditions or diseases that may benefit from the mobilization of blood stem cells include, but are not limited to, organ or cell transplantation and tumor chemo-radiotherapy, in particular autologous 1,2 or allogeneic SCT in patients with NHL, relapsed HL 4 , MM 5 , or in the recovery phase following myelosuppressive chemotherapy.
- the active ingredients of the combined preparation can be simultaneously or separately administered in formulation with pharmaceutically acceptable vehicles and excipients.
- the parenteral route of administration is preferred. Methods for the preparation of pharmaceutical compositions suitable for parenteral administration are known in the art; details can be found in " Remington: The Science and Practice of Pharmacy", Mack Publishing Co.
- the amount of active ingredients in the combined preparations according to the invention can be varied depending for instance on the administration route, on the effect sought or condition to be treated, and on the response of the patient. As a general rule, an effective amount of G-CSF and P1GF is able to produce the desired response in terms of blood stem cell mobilization.
- the patient/subject response can be monitored during the treatment, e.g.
- recombinant hG-CSF and rhP1GF are used in form of injectable solutions supplying a daily amount of the active comprised from 1 to 150, preferably from 5 to 20 ⁇ g/kg G-CSF and from 10 to 300, preferably from 20 to 150 ⁇ g/kg P1GF.
- mice Six- to 8-week-old female BALB/c mice, with body weight of 20 to 25 g, were purchased from Charles River (Milano, Italy, EU). Experimental procedures performed on animals were carried out in accordance with the guidelines of the United Kingdom Coordinating Committee on Cancer Research ( UK Coordinating Committee on Cancer Research. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer., 58:109-113, 1998 .).
- mice were injected daily, intraperitoneally (IP), for 5 days with either control vehicle (PBS/MSA), rhG-CSF alone (10 ⁇ g/d), or a combination of rhG-CSF (10 ⁇ g/d) with recombinant murine (rm)P1GF (2.5-5 ⁇ g/d). Each experiment was performed at least on three separate occasions, and three to four mice per group per time point were used.
- IP intraperitoneally
- Cytokines Recombinant human granulocyte colony-stimulating factor (rhG-CSF, Neupogen®) was from Roche (Milan, Italy, EU); rmP1GF was purchased from R&D Systems Inc., Abingdon, United Kingdom); rhP1GF was provided from Geymonat SpA (Anagni, Italy, EU).
- the standard mobilization protocol included treatment of BA-L-B/c with rhG-CSF-(10 gg/mouse, IP) once daily for 5 days.
- rmP1GF 2.5 - 5 ⁇ g/mouse, IP
- rhG-CSF 2.5 - 5 ⁇ g/mouse, IP
- Controls were injected with PBS/MSA.
- Mobilization parameters Mobilization was evaluated by white blood cell (WBC) counts, frequency and absolute numbers of colony-forming cells (CFC), absolute numbers of long-term culture-initiating cells (LTC-IC). Unless otherwise stated, animals were sacrificed two hours after the last treatment.
- WBC white blood cell
- CFC colony-forming cells
- LTC-IC long-term culture-initiating cells
- PB was harvested from the orbital plexus into heparin containing tubes. After white blood cell (WBC) counting, PB was diluted (1:4, v/v) with PBS and mononuclear cells (MNCs) were separated by centrifugation (280 g, 30 min, room temperature) on a Ficoll discontinuous density gradient. Cells were then washed twice in Iscove's modified Dulbecco's medium (IMDM, Seromed, Berlin, Germany, EU) supplemented with 10% fetal bovine serum (FBS, Stem Cell Technologies, Vancouver, Canada), 2 mM L-glutamine and antibiotics.
- IMDM Iscove's modified Dulbecco's medium
- FBS fetal bovine serum
- WBC counts were performed using heparin-anticoagulated blood and an automated counter (ADVIA 120, Bayer, Milano, Italy, EU).
- CFC Colony-forming cell assay.
- Total colony-forming cells i.e., granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E), and multilineage CFU (CFU-GEMM) were assessed in standard methylcellulose cultures.
- CFU-GM granulocyte-macrophage colony-forming units
- BFU-E erythroid burst-forming units
- CFU-GEMM multilineage CFU
- LTC-IC Long-term culture-initiating cell
- Complete medium consisted of alpha-medium supplemented with FBS (12.5%), horse serum (12.5%), L-glutamine (2 mM), 2-mercaptoethanol (10 -4 M), inositol (0.2 mM), folic acid (20 ⁇ M) plus freshly dissolved hydrocortisone (10 -6 M). Cultures were fed weekly by replacement of half of the growth medium with fresh complete medium. After 4 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells in methylcellulose cultures.
- the total number of clonogenic cells i.e., CFU-GEMM plus BFU-E plus CFU-GM
- the total number of clonogenic cells i.e., CFU-GEMM plus BFU-E plus CFU-GM
- the total number of clonogenic cells i.e., CFU-GEMM plus BFU-E plus CFU-GM
- Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by 4, which is the average output of clonogenic cells per LTC-IC ( Sutherland HJ, et al.,Blood. 1989;74:1563-70 ).
- CFCs include granulocyte-macrophage CFC (CFU-GM), erythroid burst-forming unit (BFU-E), and multipotent CFC (CFU-Mix).
- CFC data are derived from quadruplicate cultures on samples from each animal.
- CFCs include granulocyte-macrophage CFC (CFU-GM), erythroid burst-forming unit (BFU-E), and multipotent CFC (CFU-Mix).
- CFC data are derived from quadruplicate cultures on samples from each animal. The absolute number of circulating CFCs in blood is a function of the frequency of CFC multiplied by the total number of MNCs per ml blood.
- Test cells (5 - 8 x 10 6 ) were seeded into cultures containing a feeder layer of irradiated murine AFT024 cells. After 4 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells. The total number of clonogenic cells (i.e., CFU-Mix plus BFU-E plus CFU-GM) present in 4-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension.
- the absolute number of circulating LTC-ICs in blood is a function of the frequency of LTC-ICs multiplied by the total number of MNCs per ml blood.
- a third mobilization cycle consisting of rhPlGF (260 ⁇ g/kg, IV, for 5 days) plus rhG-CSF (100 ⁇ g/kg/day, SC, for 5 days) ( cycle 3 ) was administered to the same cohort of monkeys.
- the kinetics of mobilization following cycle 1 served as intra-monkey control to assess the mobilization following cycles 2 and 3.
- Mobilization parameters We analyzed the mobilization kinetics of white blood cells (WBCs), as well as frequency and absolute numbers of committed colony-forming cells (CFCs), high-proliferative potential progenitors (HPP-CFCs), and long-term culture-initiating cells (LTC-ICs). Mobilization parameters were analyzed daily during treatment (days 1 to 5), and 3 and 5 days post-cessation of therapy. Peripheral blood samples were obtained from the femoral vein of anesthetized primates (ketamin, 10 mg/kg, intramuscularly) using aseptic techniques.
- WBC counts were performed using EDTA-anticoagulated blood and an automated counter (ADVIA 120, Bayer, Milano, Italy, EU).
- CFC and HPP-CFC assays were assayed by using heparinized blood according to a previously described technique (41, 42).
- HPP-CFCs defined as macroscopically visible colonies of >1 mm in diameter of compact colony growth, were scored after 28 days of incubation from methylcellulose cultures supplemented with rhSCF (50 ng/ml), rhIL-3 (20 ng/ml), rhIL-6 (20 ng/ml), rhG-CSF (20 ng/ml), rhGM-CSF (20 ng/ml), and rhEpo (3 U/ml) (43).
- the absolute number of circulating CFCs or HPP-CFCs in blood is a function of the frequency of CFCs or HPP-CFCs multiplied by the total number of MNCs per ml blood.
- LTC-IC assays The frequency of LTC-ICs was assessed under limiting dilution conditions (44). Briefly, serial dilutions of test cells (2 x 10 5 to 3 x 10 3 ) were resuspended in 150 ⁇ L complete medium (MyelocultTM 5100, Stem Cell Technologies) consisting of alpha-medium supplemented with fetal bovine serum (12.5%), horse serum (12.5%), L-glutamine (2 mM), 2-mercaptoethanol (10 -4 M), inositol (0.2 mM), folic acid (20 ⁇ M) plus freshly dissolved hydrocortisone (10 -6 M) and plated in 96-well flat-bottom plates.
- complete medium MyelocultTM 5100, Stem Cell Technologies
- test cells 16 to 22 replicates were plated.
- Test cells were seeded into plates containing a feeder layer of irradiated (8,000 cGy) murine M2-10B4 cells (3 x 10 4 /cm2, kindly provided by Dr. C. Eaves, Terry Fox Laboratory, Vancouver, Canada) engineered by retroviral gene transfer to produce human IL-3 and G-CSF (45).
- Cultures were fed weekly, by replacement of half of the growth medium with fresh complete medium. After 5 weeks in culture, nonadherent and adherent cells from individual wells were harvested by trypsinization, washed and assayed together for the growth of CFCs. After 12 to 14 days of incubation, cultures were scored as positive
- test cells (5 - 8 x 10 6 ) were resuspended in complete medium and seeded into cultures containing a feeder layer of irradiated murine M2-10B4 cells (3 x 10 4 /cm 2 ). After 5 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells.
- the total number of clonogenic cells (i.e., CFU-GEMM plus BFU-E plus CFU-GM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension. Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by 4, which is the average output of clonogenic cells per LTC-IC.
- Circulating WBCs A 5-day administration of rhG-CSF alone induced an average 5-fold increment in the mean ( ⁇ SD) numbers of WBCs, as compared to pretreatment values. Addition of 130 or 260 ⁇ g/kg rhPlGF to rhG-CSF resulted in a modest increase of WBC values detected on day 5 of treatment.
- Mobilization was elicited at cycle 1 by rhG-CSF alone (100 ⁇ g/kg/day, SC, day 1 - 5), at cycle 2 by a combination of rhPlGF (130 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5), and at cycle 3 by a combination of rhPlGF (260 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5).
- WBC counts were analyzed daily during treatment (days 1 to 5), as well as 3 and 5 days post-cessation of therapy. Data are expressed as mean ⁇ SD.
- Mobilization was elicited at cycle 1 by rhG-CSF alone (100 ⁇ g/kg/day, SC, day 1 - 5), at cycle 2 by a combination of rhPlGF (130 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5), and at cycle 3 by a combination of rhPlGF (260 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5).
- CFCs were analyzed daily during treatment (days 1 to 5), as well as 3 and 5 days post-cessation of therapy. Data are expressed as mean ⁇ SD.
- CFCs include granulocyte-macrophage CFC (CFU-GM), erythroid burst-forming unit (BFU-E), and multipotent CFC (CFU-Mix).
- CFC data are derived from quadruplicate cultures on samples from each animal.
- Absolute values of CFCs Absolute numbers of circulating CFCs in blood were calculated as a function of the frequency of CFCs multiplied by the total number of MNCs per ml blood. As compared to baseline values, treatment with rhG-CSF alone, rhG-CSF/rhPlGF (130 ⁇ g/kg), and rhG-CSF/rhPlGF (260 ⁇ g/kg) resulted in a 85- 335- and 358-fold increase of CFCs, respectively. At cycles 2 and 3, the peak levels of CFCs were increased by 4- and 5-fold over cycle 1 (rhG-CSF alone).
- Mobilization was elicited at cycle 1 by rhG-CSF alone (100 ⁇ g/kg/day, SC, day 1 - 5), at cycle 2 by a combination of rhPlGF (130 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5), and at cycle 3 by a combination of rhPlGF (260 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5).
- CFCs were analyzed daily during treatment (days 1 to 5), as well as 3 and 5 days post-cessation of therapy. Data are expressed as mean ⁇ SD.
- CFCs include granulocyte-macrophage CFC (CFU-GM), erythroid burst-forming unit (BFU-E), and multipotent CFC (CFU-Mix).
- CFC data are derived from quadruplicate cultures on samples from each animal. The absolute number of circulating CFCs in blood is a function of the frequency of CFC multiplied by the total number of MNCs per ml blood.
- Absolute values of HPP-CFCs The absolute number of HPP-CFCs per ml blood detected on day 5 of rhG-CSF therapy was 17-fold higher than pretreatment values. Monkeys receiving the combined rhG-CSF/rhPlGF (130 ⁇ g/kg) treatment showed a 158-fold increase of HPP-CFCs as compared to baseline values. At cycle 2, the level of day-5 HPP-CFCs was increased by 5-fold over cycle 1.
- Mobilization was elicited at cycle 1 by rhG-CSF alone (100 ⁇ g/kg/day, SC, day 1 - 5), at cycle 2 by a combination of rhPlGF (130 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5), and at cycle 3 by a combination of rhPlGF (260 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5).
- HPP-CFC counts were analyzed daily during treatment (days 1 to 5), as well as 3 and 5 days post-cessation of therapy.
- HPP-CFCs data are derived from quadruplicate cultures on samples from each animal.
- the absolute number of circulating HPP-CFCs in blood is a function of the frequency of HPP-CFCs multiplied by the total number of MNGs-per ml blood.
- Absolute values of LTC-ICs Under rhG-CSF alone, absolute numbers of circulating LTC-ICs were increased by 53-fold on day 4 of treatment as compared to baseline values.
- the combined rhG-CSF/rhPlGF (130 ⁇ g/kg) treatment increased LTC-ICs by 389-fold as compared to pretreatment values, and by 15-fold as compared to rhG-CSF alone.
- Mobilization was elicited at cycle 1 by rhG-CSF alone (100 ⁇ g/kg/day, SC, day 1 - 5), at cycle 2 by a combination of rhPlGF (130 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5), and at cycle 3 by a combination of rhPlGF (260 ⁇ g/kg, IV, day 1 - 5) plus rhG-CSF (100 ⁇ g/kg/day, SC, day 1 -5).
- LTC-IC counts were analyzed daily during treatment (days 1 to 5), as well as 3 and 5 days post-cessation of therapy.
- the absolute number of circulating LTC-IC was assayed in bulk cultures. Test cells (5 - 8 x 10 6 ) were seeded into cultures containing a feeder layer of irradiated murine M2-10B4 cells. After 5 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells. The total number of clonogenic cells (i.e., CFU-Mix plus BFU-E plus CFU-GM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension. The absolute number of circulating LTC-ICs in blood is a function of the frequency of LTC-ICs multiplied by the total number of MNCs per ml blood.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200431743T SI1660115T1 (sl) | 2003-07-29 | 2004-07-23 | Farmacevtska kombinacija G-CSF in PLGF koristna za krvne matične celice |
EP04763431A EP1660115B1 (en) | 2003-07-29 | 2004-07-23 | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
PL04763431T PL1660115T3 (pl) | 2003-07-29 | 2004-07-23 | Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03017174 | 2003-07-29 | ||
EP04763431A EP1660115B1 (en) | 2003-07-29 | 2004-07-23 | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
PCT/EP2004/008245 WO2005014023A1 (en) | 2003-07-29 | 2004-07-23 | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1660115A1 EP1660115A1 (en) | 2006-05-31 |
EP1660115B1 true EP1660115B1 (en) | 2011-06-22 |
Family
ID=34130041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04763431A Expired - Lifetime EP1660115B1 (en) | 2003-07-29 | 2004-07-23 | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
Country Status (21)
Country | Link |
---|---|
US (1) | US20070036747A1 (pt) |
EP (1) | EP1660115B1 (pt) |
JP (1) | JP4855253B2 (pt) |
KR (1) | KR101192136B1 (pt) |
CN (1) | CN100534528C (pt) |
AT (1) | ATE513555T1 (pt) |
AU (1) | AU2004262909B2 (pt) |
BR (1) | BRPI0412989A (pt) |
CA (1) | CA2526244C (pt) |
DK (1) | DK1660115T3 (pt) |
ES (1) | ES2369487T3 (pt) |
IL (1) | IL173369A (pt) |
MX (1) | MXPA06000017A (pt) |
NO (1) | NO20060955L (pt) |
NZ (1) | NZ543612A (pt) |
PL (1) | PL1660115T3 (pt) |
PT (1) | PT1660115E (pt) |
RU (1) | RU2351357C2 (pt) |
SI (1) | SI1660115T1 (pt) |
WO (1) | WO2005014023A1 (pt) |
ZA (1) | ZA200509361B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
PL1853619T3 (pl) | 2005-03-02 | 2011-03-31 | Univ Maryland | 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty |
US20110118219A1 (en) | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
WO2009129208A2 (en) | 2008-04-14 | 2009-10-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress reponse |
CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
KR20120056267A (ko) | 2009-08-07 | 2012-06-01 | 토카이 파마슈티컬, 아이엔씨. | 전립선 암의 치료 |
WO2014134539A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于***性疾病的生物标记物 |
LT6161B (lt) | 2013-09-27 | 2015-06-25 | Uab Profarma | Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas |
CN114891746A (zh) * | 2021-12-21 | 2022-08-12 | 青岛今墨堂生物技术有限公司 | 一种犬全血造血干细胞的制备方法 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
DE19549232C2 (de) * | 1995-12-20 | 1998-05-20 | Boehringer Mannheim Gmbh | Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern |
US7105168B1 (en) * | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
JP2006517586A (ja) * | 2003-02-04 | 2006-07-27 | ラドウィグ インスティテュート フォー キャンサー リサーチ | 幹細胞のvegf−b及びpdgf調節 |
-
2004
- 2004-07-23 AT AT04763431T patent/ATE513555T1/de active
- 2004-07-23 ZA ZA200509361A patent/ZA200509361B/en unknown
- 2004-07-23 ES ES04763431T patent/ES2369487T3/es not_active Expired - Lifetime
- 2004-07-23 CN CNB2004800213159A patent/CN100534528C/zh not_active Expired - Fee Related
- 2004-07-23 KR KR1020057023606A patent/KR101192136B1/ko not_active IP Right Cessation
- 2004-07-23 SI SI200431743T patent/SI1660115T1/sl unknown
- 2004-07-23 EP EP04763431A patent/EP1660115B1/en not_active Expired - Lifetime
- 2004-07-23 PT PT04763431T patent/PT1660115E/pt unknown
- 2004-07-23 CA CA2526244A patent/CA2526244C/en not_active Expired - Fee Related
- 2004-07-23 MX MXPA06000017A patent/MXPA06000017A/es active IP Right Grant
- 2004-07-23 PL PL04763431T patent/PL1660115T3/pl unknown
- 2004-07-23 DK DK04763431.6T patent/DK1660115T3/da active
- 2004-07-23 RU RU2006106228/15A patent/RU2351357C2/ru not_active IP Right Cessation
- 2004-07-23 US US10/565,903 patent/US20070036747A1/en not_active Abandoned
- 2004-07-23 AU AU2004262909A patent/AU2004262909B2/en not_active Ceased
- 2004-07-23 WO PCT/EP2004/008245 patent/WO2005014023A1/en active Application Filing
- 2004-07-23 JP JP2006521487A patent/JP4855253B2/ja not_active Expired - Fee Related
- 2004-07-23 BR BRPI0412989-0A patent/BRPI0412989A/pt not_active IP Right Cessation
- 2004-07-23 NZ NZ543612A patent/NZ543612A/en not_active IP Right Cessation
-
2006
- 2006-01-26 IL IL173369A patent/IL173369A/en not_active IP Right Cessation
- 2006-02-27 NO NO20060955A patent/NO20060955L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK1660115T3 (da) | 2011-10-10 |
SI1660115T1 (sl) | 2011-10-28 |
MXPA06000017A (es) | 2006-03-21 |
CA2526244C (en) | 2012-03-20 |
EP1660115A1 (en) | 2006-05-31 |
IL173369A (en) | 2010-12-30 |
KR101192136B1 (ko) | 2012-10-16 |
PT1660115E (pt) | 2011-08-24 |
NO20060955L (no) | 2006-02-27 |
BRPI0412989A (pt) | 2006-10-03 |
NZ543612A (en) | 2008-03-28 |
PL1660115T3 (pl) | 2011-11-30 |
ES2369487T3 (es) | 2011-12-01 |
CN100534528C (zh) | 2009-09-02 |
RU2006106228A (ru) | 2007-09-10 |
US20070036747A1 (en) | 2007-02-15 |
JP4855253B2 (ja) | 2012-01-18 |
KR20060079753A (ko) | 2006-07-06 |
RU2351357C2 (ru) | 2009-04-10 |
ATE513555T1 (de) | 2011-07-15 |
WO2005014023A1 (en) | 2005-02-17 |
AU2004262909A1 (en) | 2005-02-17 |
AU2004262909B2 (en) | 2010-07-01 |
CN1826134A (zh) | 2006-08-30 |
IL173369A0 (en) | 2006-06-11 |
JP2007500157A (ja) | 2007-01-11 |
CA2526244A1 (en) | 2005-02-17 |
ZA200509361B (en) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Welte et al. | Filgrastim (r-metHuG-CSF): the first 10 years | |
EP1660115B1 (en) | Pharmaceutical combination of g-csf and plgf useful for blood stem cell | |
EP3587562B1 (en) | Methods modulating immunoregulatory effect of stem cells | |
US10046011B2 (en) | Compositions for inducing or suppressing an immune response | |
EP2999478B1 (en) | Dextran sulfate for use in mobilization of cells | |
US20140294755A1 (en) | Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor | |
US20050089507A1 (en) | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction | |
Gabrilove et al. | Granulocyte colony-stimulating factor: preclinical and clinical studies | |
Kurzrock | Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited | |
KR101144687B1 (ko) | G-csf 를 함유하는 선유아세포 동원제 및 창상 치료제 | |
Carlo-Stella et al. | Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates | |
Guillaume et al. | IL‐3 and peripheral blood stem cell harvesting | |
Farese et al. | The combined administration of daniplestim and MpL ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression | |
Pyrhönen | Systemic therapy in metastatic renal cell carcinoma | |
Carlo-Stella et al. | Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor | |
Lyman | The myeloid growth factors | |
Moore | Cytokine Interactions in Hematopoiesis: An Introduction and Overview | |
BALLARINO et al. | Interferon-α inhibits CFU-GM mobilization following chemotherapy and G-CSF administration | |
Isidori et al. | Stem Cell Mobilization: An Overview | |
Price et al. | Hematopoietic growth factors in transfusion medicine | |
Welte | 5 Granulocyte Colony Stimulating Factor (G-CSF) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060224 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
17Q | First examination report despatched |
Effective date: 20071023 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DOMPE' S.P.A. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004033199 Country of ref document: DE Effective date: 20110728 |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20110809 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20110402046 Country of ref document: GR Effective date: 20110916 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 9967 Country of ref document: SK |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20110622 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110622 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2369487 Country of ref document: ES Kind code of ref document: T3 Effective date: 20111201 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E005835 Country of ref document: EE Effective date: 20110919 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E012300 Country of ref document: HU |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20120323 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004033199 Country of ref document: DE Effective date: 20120323 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: EE Payment date: 20140630 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20140728 Year of fee payment: 11 Ref country code: PT Payment date: 20140627 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20140729 Year of fee payment: 11 Ref country code: DE Payment date: 20140808 Year of fee payment: 11 Ref country code: RO Payment date: 20140701 Year of fee payment: 11 Ref country code: MC Payment date: 20140723 Year of fee payment: 11 Ref country code: DK Payment date: 20140724 Year of fee payment: 11 Ref country code: BG Payment date: 20140717 Year of fee payment: 11 Ref country code: IE Payment date: 20140729 Year of fee payment: 11 Ref country code: CH Payment date: 20140731 Year of fee payment: 11 Ref country code: NL Payment date: 20140729 Year of fee payment: 11 Ref country code: CZ Payment date: 20140717 Year of fee payment: 11 Ref country code: FI Payment date: 20140722 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20140702 Year of fee payment: 11 Ref country code: AT Payment date: 20140722 Year of fee payment: 11 Ref country code: SE Payment date: 20140725 Year of fee payment: 11 Ref country code: TR Payment date: 20140722 Year of fee payment: 11 Ref country code: HU Payment date: 20140718 Year of fee payment: 11 Ref country code: SK Payment date: 20140722 Year of fee payment: 11 Ref country code: GB Payment date: 20140801 Year of fee payment: 11 Ref country code: ES Payment date: 20140901 Year of fee payment: 11 Ref country code: SI Payment date: 20140630 Year of fee payment: 11 Ref country code: FR Payment date: 20140729 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20140728 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20140731 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20160125 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004033199 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20150731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG Ref country code: SK Ref legal event code: MM4A Ref document number: E 9967 Country of ref document: SK Effective date: 20150723 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 513555 Country of ref document: AT Kind code of ref document: T Effective date: 20150723 Ref country code: EE Ref legal event code: MM4A Ref document number: E005835 Country of ref document: EE Effective date: 20150731 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150723 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20150801 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160202 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160331 Ref country code: SI Ref legal event code: KO00 Effective date: 20160331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150724 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150801 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150724 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160125 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160202 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150724 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20110402046 Country of ref document: GR Effective date: 20160202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150724 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150723 |